FDA Expands Rozlytrek Indication to Include Some Solid Tumors in Children at Least 1 Month Old

This expanded indication broadens the use of Rozlytrek for solid tumors to include children one month old, with the original approval in 2019 only including children one year and older.

Related Keywords

,Drug Administration ,Solid Tumors ,Pediatric ,